Talphera (TLPH) Share-based Compensation (2010 - 2026)
Talphera (TLPH) posted Share-based Compensation of $4.2 million for Q2 2026, up 5.29% on a QoQ basis from $4.0 million in Q1 2026, and up 71.43% year-over-year from $2.5 million in Q2 2025.
Analysis
Talphera (TLPH) Share-based Compensation (2010 - 2026) Analysis & Trends
Talphera has reported Share-based Compensation for 17 years, with the latest figure at $4.2 million in Q2 2026.
- On a quarterly basis, Share-based Compensation rose 71.43% year-over-year to $4.2 million in Q2 2026; TTM through Jun 2026 was $4.2 million, a 71.43% increase from a year earlier, with the FY2025 full-year figure at $2.6 million, up 46.09% from the prior year.
- Share-based Compensation was $4.2 million for Q2 2026 at Talphera, up from $4.0 million in the prior quarter.
- The five-year high for Share-based Compensation was $15.6 million in Q1 2022, with the low at -$563000.0 in Q4 2024.
- Average Share-based Compensation over 5 years is $3.0 million, with a median of $1.7 million recorded in 2024.
- The sharpest annual moves came in 2024 and 2026: Share-based Compensation tumbled 281.03% in 2024, then surged 125.08% in 2026.
- Over 5 years, Share-based Compensation stood at $652000.0 in 2022, then plunged by 52.3% to $311000.0 in 2023, then sank by 281.03% to -$563000.0 in 2024, then jumped by 46.71% to -$300000.0 in 2025, then surged by 1505.31% to $4.2 million in 2026.
- The last three Share-based Compensation figures came in at $4.2 million (Q2 2026), $4.0 million (Q1 2026), and -$300000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 83.34 Mn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | 4.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.22 Mn |
| Mar 31, 2026 | 4.00 Mn |
| Dec 31, 2025 | -300,000.00 |
| Sep 30, 2025 | 2.44 Mn |
| Jun 30, 2025 | 2.46 Mn |
| Mar 31, 2025 | 1.78 Mn |
| Dec 31, 2024 | -563,000.00 |
| Sep 30, 2024 | 1.88 Mn |
| Jun 30, 2024 | 1.93 Mn |
| Mar 31, 2024 | 1.67 Mn |
| Dec 31, 2023 | 311,000.00 |
| Sep 30, 2023 | 875,332.00 |
| Jun 30, 2023 | 885,783.00 |
| Mar 31, 2023 | 897,391.00 |
| Dec 31, 2022 | 652,000.00 |
| Sep 30, 2022 | 733,308.00 |
| Jun 30, 2022 | 15.04 Mn |
| Mar 31, 2022 | 15.64 Mn |
| Dec 31, 2021 | 1.19 Mn |
| Sep 30, 2021 | 14.38 Mn |